Clinical trial NCT03696797 - References

Diabetes — Iron Reduction for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease

Citation(s)

•   Abraham D, Rogers J, Gault P, Kushner JP, McClain DA
  Increased insulin secretory capacity but decreased insulin sensitivity after correction of iron overload by phlebotomy in hereditary haemochromatosis. Diabetologia. 2006 Nov;49(11):2546-51. doi: 10.1007/s00125-006-0445-7. Epub 2006 Sep 22.
•   Adams LA, Crawford DH, Stuart K, House MJ, St Pierre TG, Webb M, Ching HL, Kava J, Bynevelt M, MacQuillan GC, Garas G, Ayonrinde OT, Mori TA, Croft KD, Niu X, Jeffrey GP, Olynyk JK
  The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology. 2015 May;61(5):1555-64. doi: 10.1002/hep.27662. Epub 2015 Mar 20.
•   Afkhami-Ardekani M, Rashidi M
  Iron status in women with and without gestational diabetes mellitus. J Diabetes Complications. 2009 May-Jun;23(3):194-8. doi: 10.1016/j.jdiacomp.2007.11.006. Epub 2008 Apr 16.
•   Altamura S, Muckenthaler MU
  Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis. 2009;16(4):879-95. doi: 10.3233/JAD-2009-1010.
•   Andrews Guzman M, Arredondo Olguin M
  Association between ferritin, high sensitivity C-reactive protein (hsCRP) and relative abundance of Hepcidin mRNA with the risk of type 2 diabetes in obese subjects. Nutr Hosp. 2014 Sep 1;30(3):577-84. doi: 10.3305/nh.2014.30.3.7647.
•   Ausk KJ, Ioannou GN
  Is obesity associated with anemia of chronic disease? A population-based study. Obesity (Silver Spring). 2008 Oct;16(10):2356-61. doi: 10.1038/oby.2008.353. Epub 2008 Jul 24.
•   Beaton MD, Chakrabarti S, Adams PC
  Inflammation is not the cause of an elevated serum ferritin in non-alcoholic fatty liver disease. Ann Hepatol. 2014 May-Jun;13(3):353-6.
•   Beutler E, Felitti V, Ho NJ, Gelbart T
  Relationship of body iron stores to levels of serum ferritin, serum iron, unsaturated iron binding capacity and transferrin saturation in patients with iron storage disease. Acta Haematol. 2002;107(3):145-9. doi: 10.1159/000057632.
•   Bowers K, Yeung E, Williams MA, Qi L, Tobias DK, Hu FB, Zhang C
  A prospective study of prepregnancy dietary iron intake and risk for gestational diabetes mellitus. Diabetes Care. 2011 Jul;34(7):1557-63. doi: 10.2337/dc11-0134.
•   Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, Edwards CQ, Kushner JP
  Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med. 2000 Nov 23;343(21):1529-35. doi: 10.1056/NEJM200011233432104.
•   Buysschaert M, Paris I, Selvais P, Hermans MP
  Clinical aspects of diabetes secondary to idiopathic haemochromatosis in French-speaking Belgium. Diabetes Metab. 1997 Sep;23(4):308-13.
•   Cheng HL, Bryant C, Cook R, O'Connor H, Rooney K, Steinbeck K
  The relationship between obesity and hypoferraemia in adults: a systematic review. Obes Rev. 2012 Feb;13(2):150-61. doi: 10.1111/j.1467-789X.2011.00938.x. Epub 2011 Oct 10.
•   Cooksey RC, Jones D, Gabrielsen S, Huang J, Simcox JA, Luo B, Soesanto Y, Rienhoff H, Abel ED, McClain DA
  Dietary iron restriction or iron chelation protects from diabetes and loss of beta-cell function in the obese (ob/ob lep-/-) mouse. Am J Physiol Endocrinol Metab. 2010 Jun;298(6):E1236-43. doi: 10.1152/ajpendo.00022.2010. Epub 2010 Mar 30.
•   Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B
  Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab. 1993 Aug;77(2):478-83. doi: 10.1210/jcem.77.2.8345055.
•   Dongiovanni P, Fracanzani AL, Fargion S, Valenti L
  Iron in fatty liver and in the metabolic syndrome: a promising therapeutic target. J Hepatol. 2011 Oct;55(4):920-32. doi: 10.1016/j.jhep.2011.05.008. Epub 2011 Jun 28.
•   Duvnjak M, Barsic N, Tomasic V, Lerotic I
  Genetic polymorphisms in non-alcoholic fatty liver disease: clues to pathogenesis and disease progression. World J Gastroenterol. 2009 Dec 28;15(48):6023-7. doi: 10.3748/wjg.15.6023.
•   Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P, Taioli E, Valenti L, Fiorelli G
  Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol. 2001 Aug;96(8):2448-55. doi: 10.1111/j.1572-0241.2001.04052.x.
•   Fargnoli JL, Fung TT, Olenczuk DM, Chamberland JP, Hu FB, Mantzoros CS
  Adherence to healthy eating patterns is associated with higher circulating total and high-molecular-weight adiponectin and lower resistin concentrations in women from the Nurses' Health Study. Am J Clin Nutr. 2008 Nov;88(5):1213-24. doi: 10.3945/ajcn.2008.26480.
•   Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W
  Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes. 2002 Apr;51(4):1000-4. doi: 10.2337/diabetes.51.4.1000.
•   Fleming DJ, Tucker KL, Jacques PF, Dallal GE, Wilson PW, Wood RJ
  Dietary factors associated with the risk of high iron stores in the elderly Framingham Heart Study cohort. Am J Clin Nutr. 2002 Dec;76(6):1375-84. doi: 10.1093/ajcn/76.6.1375.
•   Ford ES, Cogswell ME
  Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care. 1999 Dec;22(12):1978-83. doi: 10.2337/diacare.22.12.1978.
•   Forouhi NG, Harding AH, Allison M, Sandhu MS, Welch A, Luben R, Bingham S, Khaw KT, Wareham NJ
  Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia. 2007 May;50(5):949-56. doi: 10.1007/s00125-007-0604-5. Epub 2007 Mar 2.
•   Gabrielsen JS, Gao Y, Simcox JA, Huang J, Thorup D, Jones D, Cooksey RC, Gabrielsen D, Adams TD, Hunt SC, Hopkins PN, Cefalu WT, McClain DA
  Adipocyte iron regulates adiponectin and insulin sensitivity. J Clin Invest. 2012 Oct;122(10):3529-40. doi: 10.1172/JCI44421. Epub 2012 Sep 10.
•   Gao Y, Li Z, Gabrielsen JS, Simcox JA, Lee SH, Jones D, Cooksey B, Stoddard G, Cefalu WT, McClain DA
  Adipocyte iron regulates leptin and food intake. J Clin Invest. 2015 Sep;125(9):3681-91. doi: 10.1172/JCI81860. Epub 2015 Aug 24.
•   Houschyar KS, Ludtke R, Dobos GJ, Kalus U, Broecker-Preuss M, Rampp T, Brinkhaus B, Michalsen A
  Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. BMC Med. 2012 May 30;10:54. doi: 10.1186/1741-7015-10-54.
•   Jehn M, Clark JM, Guallar E
  Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care. 2004 Oct;27(10):2422-8. doi: 10.2337/diacare.27.10.2422.
•   Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB
  Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA. 2004 Feb 11;291(6):711-7. doi: 10.1001/jama.291.6.711.
•   Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group
  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512.
•   Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, Sanyal AJ, Nelson JE; NASH Clinical Research Network
  Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012 Jan;55(1):77-85. doi: 10.1002/hep.24706. Epub 2011 Dec 6.
•   Koziol JA, Ho NJ, Felitti VJ, Beutler E
  Reference centiles for serum ferritin and percentage of transferrin saturation, with application to mutations of the HFE gene. Clin Chem. 2001 Oct;47(10):1804-10.
•   Kusminski CM, Holland WL, Sun K, Park J, Spurgin SB, Lin Y, Askew GR, Simcox JA, McClain DA, Li C, Scherer PE
  MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat Med. 2012 Oct;18(10):1539-49. doi: 10.1038/nm.2899. Epub 2012 Sep 9.
•   Lorenzo C, Wagenknecht LE, Rewers MJ, Karter AJ, Bergman RN, Hanley AJ, Haffner SM
  Disposition index, glucose effectiveness, and conversion to type 2 diabetes: the Insulin Resistance Atherosclerosis Study (IRAS). Diabetes Care. 2010 Sep;33(9):2098-103. doi: 10.2337/dc10-0165.
•   Murali AR, Gupta A, Brown K
  Systematic review and meta-analysis to determine the impact of iron depletion in dysmetabolic iron overload syndrome and non-alcoholic fatty liver disease. Hepatol Res. 2018 Feb;48(3):E30-E41. doi: 10.1111/hepr.12921. Epub 2017 Jul 20.
•   Qiu C, Zhang C, Gelaye B, Enquobahrie DA, Frederick IO, Williams MA
  Gestational diabetes mellitus in relation to maternal dietary heme iron and nonheme iron intake. Diabetes Care. 2011 Jul;34(7):1564-9. doi: 10.2337/dc11-0135.
•   Sharifi F, Nasab NM, Zadeh HJ
  Elevated serum ferritin concentrations in prediabetic subjects. Diab Vasc Dis Res. 2008 Mar;5(1):15-8. doi: 10.3132/dvdr.2008.003.
•   Toyokuni S
  Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 2009 Jan;100(1):9-16. doi: 10.1111/j.1349-7006.2008.01001.x. Epub 2008 Oct 23.
•   Valenti L, Fracanzani AL, Bugianesi E, Dongiovanni P, Galmozzi E, Vanni E, Canavesi E, Lattuada E, Roviaro G, Marchesini G, Fargion S
  HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2010 Mar;138(3):905-12. doi: 10.1053/j.gastro.2009.11.013. Epub 2009 Nov 18.
•   Valenti L, Fracanzani AL, Dongiovanni P, Rovida S, Rametta R, Fatta E, Pulixi EA, Maggioni M, Fargion S
  A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol. 2014 Mar 21;20(11):3002-10. doi: 10.3748/wjg.v20.i11.3002.
•   Wilson JG, Lindquist JH, Grambow SC, Crook ED, Maher JF
  Potential role of increased iron stores in diabetes. Am J Med Sci. 2003 Jun;325(6):332-9. doi: 10.1097/00000441-200306000-00004.
•   Zhang W, Iso H, Ohira T, Date OC, Tanabe N, Kikuchi S, Tamakoshi A
  Associations of dietary iron intake with mortality from cardiovascular disease: the JACC study. J Epidemiol. 2012;22(6):484-93. doi: 10.2188/jea.je20120006. Epub 2012 Sep 15.

Iron Reduction by Phlebotomy for the Treatment of Diabetes and Nonalcoholic Fatty Liver Disease

Details for clinical trial NCT03696797